Latest News
Latest Financial Results
Q2 2024
Quarter Ended Jun 30, 2024
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
Company Overview
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, The Company’s pipeline includes multiple product candidates developed from its proprietary RAMP drug innovation and prodrug technology engines, using the same clinically validated kinase target. The Company is headquartered in Atlanta with additional offices in Lexington, Massachusetts.